Home・Aandelen Lijst・Pfizer

Pfizer

Open

SectorGezondheidszorg

25.36 1.2

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.71

Max

25.63

Belangrijke statistieken
By Trading Economics
Inkomsten	4.3B 2.7B
Verkoop	-3.1B 14B
K/W Sectorgemiddelde	18.832 64.641
EPS	0.75
Dividendrendement	7.01
Winstmarge	18.656
Werknemers	75,000
EBITDA	4.3B 5B

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+13.95% upside

Dividenden
By Acuity
Dividendrendement Sectorgemiddelde	7.01% 2.31%
Volgende Winsten	4 aug 2026
Volgende dividenddatum	1 sep 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-9.7B 140B
Vorige openingsprijs	24.16
Vorige sluitingsprijs	25.36

Nieuwssentiment

By Acuity

32%

68%

100 / 340 Rangschikking in Healthcare

Pfizer Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 23:46 UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

31 jul 2026, 23:06 UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

30 jul 2026, 23:26 UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

29 jul 2026, 23:16 UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

28 jul 2026, 23:26 UTC

Pfizer Inc shares are lower in after-market hours, reversing an earlier gain. The stock remains above its 20-day moving average.

27 jul 2026, 18:56 UTC

Pfizer Inc is trading higher, driven by gains in the Pharmaceuticals sub-sector. Shares pulled back earlier in the session from a session high.

24 jul 2026, 18:06 UTC

Pfizer Inc. shares are lower today, reflecting broader market trends. Earlier, shares fell significantly before partially recovering amid declining crude oil prices.

23 jul 2026, 09:41 UTC

News

Pfizer Inc. shares are higher in pre-market trading following FDA acceptance of a Priority Review for TALZENNA in combination with XTANDI for prostate cancer.

22 jul 2026, 23:02 UTC

News

Pfizer Inc. shares are higher in after-market hours following the FDA's acceptance of a Priority Review for TALZENNA and XTANDI in prostate cancer treatment.

21 jul 2026, 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

20 jul 2026, 23:16 UTC

Pfizer Inc shares are higher in after-market trading, maintaining above their 20-day moving average despite broader market pressures from rising treasury yields.

Peer Vergelijking

Prijswijziging

Pfizer Prognose

Koersdoel

By TipRanks

13.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.5 USD 13.95%

Hoogste 35 USD

Laagste 25 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pfizer - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

22 ratings

Buy

Hold

Sell

Gebaseerd op 22 analisten die aandelenratings hebben gegeven aan Pfizer - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

100 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.